B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5
B of A Securities analyst David Li maintains BeiGene (NASDAQ:BGNE) with a Neutral and lowers the price target from $180 to $152.5.
Zai Lab Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/25/2024 — Cantor Fitzgerald Reiterates → Overweight 02/29/2024 257.53% Citigroup $123 → $66 Maintains
Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research
The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.
WuXi AppTec Goes Ex Dividend Tomorrow
Hangzhou Tigermed Consulting Goes Ex Dividend Tomorrow
The total relief rate of Xidacilone race reaches 94%, and sales growth is expected.
On June 4th, Genscript Bio (1548.HK, referred to as "Genscript") announced that its subsidiary, Legend Biotech (LEGN.O), released the results of Phase 2 CARTITUDE-2 (Siltuximab) Cohort D study for the treatment of multiple myeloma patients for the first time at the ASCO Annual Meeting.